Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

August 08, 2005 06:00 ET

Swiss Medica Launches Medical Channel Distribution of 024 Fibromyalgia

TORONTO, ONTARIO--(CCNMatthews - Aug. 8, 2005) - Swiss Medica Inc. (OTCBB:SWME) is pleased to announce that ProHealth has begun offering O24 Fibromyalgia to its customers through its online website, www.prohealth.com. Customers can immediately directly order O24 Fibromyalgia by searching for product code 5099 or "soreness" on the ProHealth website. ProHealth is beginning a substantial promotion for the O24 Fibromyalgia product to its customer base this week.

Pro Health's CEO, Dennis Schoen, stated, "As the largest private fundraiser for Fibromyalgia and Chronic Fatigue Syndrome, Pro Health is pleased to provide a well-researched product to its patients and professional customers. We look forward to hearing positive results from our customers."

ProHealth, Inc. the publisher of the largest Fibromyalgia and Chronic Fatigue Syndrome web site, Immune Support.com is proud to introduce Swiss Medica's 024 Fibromyalgia product. Pro Health's multi-pronged launch of this product, formulated to improve the lives of Fibromyalgia patients, includes an emailing to its subscribers and prominent inclusion on Immune Support, where eight million people visited last year for the latest news on Fibromyalgia and Chronic Fatigue Syndrome research, interviews, treatment options and support. Additionally, Pro Health will actively support distribution through its network of 5,000 physicians.

"We now have a sales force on the ground detailing health care professionals," said Grant Johnson, President and COO of Swiss Medica. "This element broadens and accelerates our continued growth."

O24 Fibromyalgia is the first product of its kind developed to specifically address the symptoms of long term pain associated with the fibromyalgia syndrome and is a patented and clinically tested, strong and safe, all-natural, over-the-counter health product. Management anticipates that the recently launched O24 Fibromyalgia™ will be available in approximately 14,000 retail stores across the United States by September 30, 2005.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com

Swiss Medica's flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica
    David Jones
    Investor Relations Contact
    1 866 485 4243
    or
    Fusion Communications
    Dean Mailey
    Public Relations Contact
    (604) 218-6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Stan Froelich, VP, Media Relations
    Financial Media Contact
    (212) 888-0044
    sfroelich@sternco.com